NEW YORK (GenomeWeb News) – CardioDx today said that its laboratory in Palo Alto, Calif., has been accredited by the College of American Pathologists.
The company offers the Corus CAD gene expression test for evaluating patients with signs and symptoms of obstructive coronary artery disease through the laboratory, which is also CLIA certified and licensed by the State of New York.
Late last month, CardioDx announced a deal with Core Diagnostics India to offer Corus CAD in India. Samples will be analyzed at CardioDx's lab.
In addition, the company raised $58 million last summer to support commercialization of the test.
As part of the CAP accreditation process, inspectors examine the laboratory's records, quality control procedures, equipment, facilities, safety program, and overall lab management to ensure they meet CAP requirements.